Ken Lau

Ken Lau and Eunyoung Choi named 2024 Stanley Cohen Innovation Fund awardees

Grant funds quest to expand immunotherapy efficacy for colorectal cancer  

The study seeks to understand the mechanisms of colorectal cancer and builds on recent Vanderbilt research.

Ken Lau, PhD, left, and Bob Coffey, MD, have made several important discoveries about colorectal cancer that are aiding the search for new, more effective therapies. (photo by Erin O. Smith)

Colorectal cancer ‘cartography’ reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body’s immune system.

Colon cancer researchers awarded NCI grant for study of early lesions

Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.

C. difficile may contribute to colorectal cancer: study

A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.

Probing the tumor microenvironment

Vanderbilt researchers used single-cell sequencing, imaging, and computational approaches to characterize the colonic tumor microenvironment, providing important insights to the components that play roles in colorectal tumor pathogenesis.

1 2